In the majority of patients with chronic myelogenous leukemia (CML), the Philadelphia chromosome (Ph þ ), t(9;22)(q34;q11.2), can be identified easily by conventional cytogenetic analysis of bone marrow specimens. The development of additional chromosomal abnormalities in Ph-positive metaphases, or 'clonal evolution', reflects the genetic instability frequently associated with advanced stages of the disease. 1 Clonal evolution is a criterion for accelerated phase, has been reported in up to 80% of patients in blast phase 1 and has been linked to worse outcomes in patients with CML treated with the tyrosine kinase inhibitor (TKI) imatinib mesylate. 1 The presence of clonal chromosomal abnormalities in Phnegative cells has been described occasionally in patients with CML receiving interferon-a (IFN-a), 2 and is an increasingly recognized occurrence in patients treated with imatinib and other TKIs (for example, dasatinib, nilotinib and bosutinib). 1, 3 These abnormalities appear in up to 15% of patients treated with imatinib, but are frequently transient and rarely associated with adverse clinical consequences. However, some reports have associated the development of these cytogenetic abnormalities with secondary myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). 4, 5 Thus far, all reports have described the development of these abnormalities in bone marrow cells. We herein report the first case of Ph-negative extramedullary (cutaneous) myeloid leukemia in a patient with CML who exhibited simultaneously clonal abnormalities of chromosomes 7 and 11 in both Ph-positive and Ph-negative cells in bone marrow. Therapy with the potent TKI nilotinib led to a response in the bone marrow and peripheral blood with a significant decrease in BCR-ABL1 transcripts, but failed to arrest the progression of cutaneous Ph-negative AML lesions.
A 73-year-old man sought medical attention in May 2005 because of a skin lesion on the inner aspect of his left knee. An excisional biopsy performed at an outside facility was reportedly consistent with a 'hematologic disorder'. His white blood cell (WBC) count was 77 Â 10 9 /l; a bone marrow aspiration and core biopsy were hypercellular (90%) and consistent with CML in chronic phase. Fluorescence in situ hybridization (FISH) studies revealed the presence of Ph þ in 95% of the interphase nuclei examined. Therapy with imatinib 800 mg daily was begun in July 2005 but the dose was reduced to 400 mg daily after 10 days owing to myalgias and fatigue. In October 2005, the left knee lesion recurred and an excisional biopsy was reported as AML. Therapy with imatinib was continued, and the patient was referred to our institution for a second opinion in February 2006. At that time, he was found to have several erythematous plaques and subcutaneous nodules suggestive of leukemia cutis. A complete blood count (CBC) showed a WBC of 1.2 Â 10 9 /l (neutrophils 24%, lymphocytes 44% and monocytes 32%), hemoglobin 10.1 g/dl and platelets 36 Â 10 9 /l. A repeat bone marrow aspiration and core biopsy were hypercellular with 4% blasts. Conventional cytogenetic studies revealed the presence of three clones: 46,XY,der(7)t(7;11)(p12;p11.2)add(7)(q35),der(11) add(11)(p11.2) in 14 metaphases, 46,XY,der(7)t(7;11)(p12;p11.2) add(7)(q35),t(9;22)(q34;q11.2),add(11)(p11.2) in three metaphases and a normal diploid male karyotype in three metaphases. FISH studies performed on metaphases obtained from the bone marrow using a whole chromosome painting probe to chromosome 11 (Cytocell Inc., Windsor, CT, USA) confirmed the presence of chromosome 11 material translocated to the short arm of one of the two chromosomes 7. FISH studies for BCR/ABL1 rearrangement (Vysis LSI bcr/abl ES probe) performed on bone marrow demonstrated that 11.5% of the interphase nuclei were positive for the translocation. However, FISH studies performed on formalin-fixed, paraffin-embedded tissue sections of the skin biopsy were BCR-ABL1-negative. Molecular diagnostic studies performed on bone marrow demonstrated a BCR-ABL1/ABL1 ratio of 15.26%, and there was no evidence of mutations in the tyrosine kinase domain of ABL1 or in the FLT3, RAS and JAK2 genes. A biopsy of a new skin lesion on the left upper arm showed an infiltrate composed of numerous mediumsized blasts. Immunohistochemical stains performed on fixed, paraffin-embedded tissue sections showed that the blasts were positive for CD43 and CD68, and negative for myeloperoxidase, lysozyme, TdT, CD3 and PAX-5/BSAP, consistent with myeloid lineage. FISH studies performed on tissue sections obtained from the skin biopsy were again negative for BCR-ABL1 rearrangement. Therapy with nilotinib at 400 mg orally twice daily was started on early February 2006. Over the ensuing 8 weeks, the patient noticed the appearance of new nodular skin lesions on arms, legs, back and abdomen. Bone marrow aspiration and core biopsy showed 6% blasts and were consistent with CML in chronic phase. Conventional cytogenetic analysis revealed the presence of two clones: 46,XY,der(7)t(7;11)(p12;p11.2)add(7)-q(35),add(11)(p11.2) in 17 metaphases and a normal diploid male karyotype in three metaphases. The BCR-ABL/ABL1 ratio in peripheral blood had decreased to 2.90%. An excisional skin biopsy obtained from a nodular lesion on the left inner thigh demonstrated an infiltrate composed of medium-to-large blastic cells extending into the deep dermis. Immunohistochemical stains showed that the blasts were positive for CD68 and negative for myeloperoxidase, CD117 and CD34, similar to the previous skin biopsy. FISH studies performed on interphase nuclei on formalin-fixed, paraffin-embedded tissue sections and of cells obtained by fine-needle aspiration (FNA) again failed to detect the BCR-ABL1 rearrangement, but identified a population of cells in the FNA specimen with a single ABL1 signal, indicating either deletion of an ABL1 gene or monosomy 9. Therapy with nilotinib was discontinued and the patient received systemic chemotherapy for induction of remission of AML.
The incidence of cytogenetic abnormalities in Ph-negative metaphases in patients with CML treated with TKIs ranges from 2 to 17%. 5 This has been occasionally linked with development of MDS or AML. 4, 5 To our knowledge, this is the first instance of extramedullary disease arising from a Ph-negative clone in a patient with CML responding to imatinib and harboring both Phpositive (that is, clonal evolution) and Ph-negative clones bearing abnormalities of chromosomes 7 and 11 (Figure 1) . The Ph-negative clone was synchronously observed in BCR-ABL1-negative myeloid blasts infiltrating the skin at diagnosis, suggesting that the Ph-negative clone found in the bone marrow was responsible for the leukemia cutis. Not unexpectedly, therapy with nilotinib led to a significant decrease in peripheral blood BCR-ABL1/ABL1 ratio, but failed to arrest the progression of AML in the skin. A retrospective study of 1701 patients with CML receiving imatinib therapy at the MD Anderson Cancer Center identified three patients (0.1%) with chromosomal abnormalities in Ph-negative metaphases. 4 A diagnosis of AML was made in all three patients according to the World Health Organization (WHO) criteria; two had experienced rapid progression to AML after an initial diagnosis of high-risk MDS.
A crucial difference between clonal evolution and the acquisition of cytogenetic abnormalities in Ph-negative metaphases is that the former is considered an evolutionary step independent but likely related to the Ph chromosome, whereas the latter is a genetic event probably independent of the primary Ph-positive clone. Supporting this hypothesis is the fact that small-molecule TKIs, which target cells that harbor the hybrid BCR-ABL1 tyrosine kinase, can simultaneously suppress the Ph þ chromosome and the cytogenetic abnormalities harbored by Ph-positive metaphases resulting in response to therapy in patients with clonal evolution. In contrast, Ph-negative cells bearing additional cytogenetic abnormalities are not only insensitive to TKIs, but frequently evolve as the patient responds to these agents. 6 This is exemplified by the lack of response to the potent TKI nilotinib of the Ph-negative metaphases harboring cytogenetic abnormalities in the skin and bone marrow in the present case, despite the cytogenetic elimination of the Ph þ clone and a remarkable reduction in BCR-ABL1 transcripts.
The mechanism by which Ph-negative cells acquire additional cytogenetic abnormalities is unknown. It has been proposed that imatinib itself may directly contribute to this phenomenon. However, imatinib is not mutagenic, based upon standard preclinical testing, and a clastogenic effect was observed only at concentrations significantly higher than therapeutic levels. In addition, this phenomenon has been observed after therapy with interferon for CML, and even in other diseases, such as MDS, after therapy with lenalidomide. Alternatively, imatinib could unmask clonal Ph-negative hematopoiesis by suppressing the Ph-positive clone. It is tempting to hypothesize that, by developing a cytogenetic abnormality, a normal hematopoietic stem cell would develop a propensity for further mutational events, such as the acquisition of a Ph þ chromosome. In this scenario, both Ph-positive and Ph-negative cells would carry the same cytogenetic abnormalities. This phenomenon is extremely rare and has been reported in only two other patients treated with imatinib, one with trisomy 8 7 and another with t(2;11) in bone marrow samples. 8 The present case illustrates the increasing recognition of cytogenetic abnormalities in Ph-negative cells in patients with CML treated with TKIs, and their association with progression to MDS or AML. Moreover, it suggests that these abnormalities are not exclusively limited to the bone marrow and underscores the importance of close cytogenetic monitoring of these patients, to allow for an early detection of these rare aberrancies.
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